Safety of Stereotactic Body Radiation Therapy for Seven Ipsilateral Lung lesions

Bernard, Mark; Critchfield, Lana Sanford; Kudrimoti, Mahesh

doi:10.7759/cureus.8759

Cited by 2 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In May 2020, Bernard et al reported the case of a patient with five metastatic lung lesions that were treated synchronously with SBRT, followed by two additional lesions also treated synchronously with SBRT, for a total of seven lesions in the same lung, separated by less than 5 cm. After a 14-month follow-up, the authors found no progression and no significant late side effects [ 71 ].…”

Section: Eligible Patientsmentioning

confidence: 99%

Current Evidence for Stereotactic Body Radiotherapy in Lung Metastases

et al. 2021

View full text Add to dashboard Cite

Lung metastases are the second most common malignant neoplasms of the lung. It is estimated that 20–54% of cancer patients have lung metastases at some point during their disease course, and at least 50% of cancer-related deaths occur at this stage. Lung metastases are widely accepted to be oligometastatic when five lesions or less occur separately in up to three organs. Stereotactic body radiation therapy (SBRT) is a noninvasive, safe, and effective treatment for metastatic lung disease in carefully selected patients. There is no current consensus on the ideal dose and fractionation for SBRT in lung metastases, and it is the subject of study in ongoing clinical trials, which examines different locations in the lung (central and peripheral). This review discusses current indications, fractionations, challenges, and technical requirements for lung SBRT.

show abstract

Section: Eligible Patientsmentioning

confidence: 99%

Current Evidence for Stereotactic Body Radiotherapy in Lung Metastases

et al. 2021

View full text Add to dashboard Cite

show abstract

“…We know that studies have been conducted on patients with multiple lung metastases. Bernand et al conducted a study on a patient with seven metastases in one lung and recommended the use of SBRT, especially in metastatic patients with a high possibility of survival (13). Kelly (15).…”

Section: Introductionmentioning

confidence: 99%

Stereotactic Radiotherapy for Multiple Lung Metastases: Early Clinical Outcomes

Tuğrul¹

2022

esmj

View full text Add to dashboard Cite

Introduction: Oligometastatic lung cancers are usually small in size and high doses of radiation increase the chance of local control. In this study, it was aimed to treat patients with stereotactic body radiotherapy (SBRT) technique and to examine the early effects of treatment in order to control these tumors of patients whose primary tumor was controlled but 3 and 4 metastases developed in their lungs. Methods: Computed tomography (CT) images of seven patients with three to four lung metastases were acquired using 2 mm sections. Treatment plans were prepared to deliver a total of 48 Gray (Gy) in four fractions at two isocenters. All plans were created using the Monaco treatment planning system (TPS) and the MonteCarlo algorithm at a filter-free 6MV energy (6FFF - dose rate: 1600 MU/min). During all these processes, the exact target was irradiated through active breathing control (ABC). Patients were administered a pulmonary function test (PFT) before and after the treatment and the results were compared. Results: 100% of the intended dose was prescribed to the tumor volumes of the patients. Critical organ doses met the TG101 standards. The maximum dose of the plans was kept below 120%. All treatment plans reached desired values and were clinically accepted. Conclusion: Local control was achieved in the patients and there was no grade 3-4-5 radiation pneumonia (RP). In particular, patients with severe pulmonary comorbidities should be carefully monitored for RP during the few months of follow-up after SBRT. Depending on the patient's condition (holding the breath, being stable, etc.) or the characteristics of the linear accelerator, SBRT can be safely administered to metastases at two or three isocenters and the metastases can be controlled when patients with locally controlled primary tumors develop multiple distant metastases in the lungs.

show abstract

Safety of Stereotactic Body Radiation Therapy for Seven Ipsilateral Lung lesions

Abstract: Bernard et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Cited by 2 publications

References 8 publications

Current Evidence for Stereotactic Body Radiotherapy in Lung Metastases

Current Evidence for Stereotactic Body Radiotherapy in Lung Metastases

Stereotactic Radiotherapy for Multiple Lung Metastases: Early Clinical Outcomes

Contact Info

Product

Resources

About